Published online Feb 10, 2016. doi: 10.5306/wjco.v7.i1.9
Peer-review started: June 14, 2015
First decision: September 17, 2015
Revised: October 2, 2015
Accepted: December 1, 2015
Article in press: December 2, 2015
Published online: February 10, 2016
Processing time: 235 Days and 2.9 Hours
The development of liver metastases is a common clinical entity in the clinical course of colorectal cancer. For patients with isolated liver involvement, surgical resection is the only treatment that can provide a chance of prolonged survival and cure. However, most of these patients are not initially eligible for the surgery. Selected patients with initially considered to have unresectable disease may become resectable after systemic (chemotherapy ± biological therapy) and loco-regional treatment modalities including hepatic arterial infusion. Patients who have colorectal liver metastases ideally should be referred to a multidisciplinary cancer care team in order to identify the most optimal management approach.
Core tip: A subset of patients presenting with unresectable colorectal liver metastases (CLM) patients may become eligible for resection following systemic (chemotherapy ± biological therapy) and loco-regional treatments, including hepatic arterial infusion. After successful complete (R0) resection of liver lesions, these patients can achieve long-term survival. Therefore, all patients with CLM should be discussed in a multidisciplinary team meeting to identify appropriate treatment options.